ASND
$191.49
Ascendis Pharma ADR
$1.14
.60%
ASND
Earnings Whisper ®
N/A
3rd Quarter September 2025
Consensus:  ($0.68)
Revenue:  N/A
Thursday
Nov 6
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ASND reports earnings?
Beat
Meet
Miss

Where is ASND's stock price going from here?
Up
Flat
Down
Stock chart of ASND
Analysts
Summary of analysts' recommendations for ASND
Score
Grade
Pivots
Resistance
$227.39
$213.69
$202.59

$188.89

Support
$177.79
$164.09
$152.99
Tweet
Growth
Description
Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.
Peers
Vertex PharmaceuticalsBioMarin PharmaceuticalBristol Myers SquibbEli LillyRegeneron PharmaceuticalsMerck & Co.Johnson & JohnsonARRAY TechnologiesPfizerUltragenyx Pharmaceutical